Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 11, 2016 6:54 PM ET


Company Overview of Gen9, Inc.

Company Overview

Gen9, Inc. transforms synthetic biology by creating technologies for biopharmaceuticals, fine chemicals, and bio-fuels industries. It provides BioFAB for gene synthesis technologies and GeneBytes to enable gene-scale synthetic biology. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

500 Technology Square

First Floor

Suite 130

Cambridge, MA 02139

United States

Founded in 2009





Key Executives for Gen9, Inc.

Chief Executive Officer and President
Age: 43
Co-Founder, Executive Chairman, Chief Technology Officer and Member of Scientific Advisory Board
Co-Founder, Member of Scientific Advisory Board and Director
Co-Founder, Member of Scientific Advisory Board and Director
Age: 61
Chief Operating Officer
Compensation as of Fiscal Year 2015.

Gen9, Inc. Key Developments

Gen9, Inc. Announces Executive Appointments

Gen9, Inc. announced the appointment of Leda Notchey as Vice President of Marketing and Matt Marano as Senior Director of Business Development. In her new role, Ms. Notchey will oversee Gen9's strategic marketing functions, including market development, product management, brand, and corporate communications. Ms. Notchey brings more than 20 years of experience in life sciences marketing, business leadership and commercial operations. She joins Gen9 from Thermo Fisher Scientific where she was most recently Director of Global Channel Development, Biosciences.

Gen9, Inc. Launches of GeneByte Plus DNA Constructs to Enable Pathway and Genome Building

Gen9, Inc. announced the commercial launch of GeneByte Plus(TM) DNA constructs, synthesized at lengths ranging from 3,000 to 10,000 base pairs. This new capacity extends the company's product portfolio, which also includes synthesized DNA below 3,000 base pairs in length. Just as chemical engineering transformed 20th century manufacturing with cutting-edge building blocks that led to important new materials such as nylon and plastic, engineered DNA will provide the next-generation building blocks needed for environmentally responsible, efficient manufacturing in the 21st century. High-accuracy constructs in the multi-kilobase range will enable scientists in biology and other industrial fields to study the behavior of full genes, metabolic pathways, distant genetic elements, genomes, and other aspects of DNA that cannot currently be interrogated with shorter synthetic DNA fragments.

Gen9 Appoints Jennifer A. Camacho as Chief Legal and Business Counsel

Gen9, Inc. announced the appointment of Jennifer A. Camacho as Chief Legal and Business Counsel. In this new role, Ms. Camacho will lead the company's intellectual property strategy, regulatory compliance and general legal affairs. As a member of the executive team, she will report to Chief Executive Officer Kevin Munnelly. Camacho joins Gen9 from the Boston office of Greenberg Traurig, LLP, where she was a partner focused on intellectual property. In this capacity, she represented clients in synthetic biology, industrial biotechnology, pharmaceuticals, regenerative medicine, protein engineering, chemistry, and biofuels, among others. Prior, Ms. Camacho was with Proskauer Rose LLP, where she was Chief Patent Counsel. Her corporate experience includes vice president of IP at Codon Devices. Camacho is routinely recognized for her leadership and work, particularly in the life sciences and emerging technology sectors.

Similar Private Companies By Industry

Company Name Region
GB Lifesciences Corporation United States
Selventa, Inc. United States
Cortexyme, Inc. United States
Luna Analytics United States
Immatics US Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Gen9, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at